Akiram Therapeutics: Cohort 2a completed and cohort 2b cleared to start in Phase I trial of AKIR001

Akiram Therapeutics completed cohort 2a of its Phase I dose‑escalation trial of 177Lu‑AKIR001—an anti‑CD44v6 antibody conjugated to lutetium‑177—reporting no dose‑limiting toxicities, a favorable safety profile and encouraging tumor uptake after testing a higher activity dose than the run‑in cohort. The Safety Review Committee has cleared cohort 2b to start, which will raise the protein dose while keeping the same radioactivity to identify the optimal protein dose for remaining cohorts; the trial (sponsored and run at Karolinska University Hospital, NCT06639191) enrolls patients with advanced thyroid, head and neck, gynecological squamous and non‑small cell lung cancers. The result lowers near‑term development risk by confirming tolerability and target engagement and advances AKIR001 toward protein‑dose optimization needed to define a therapeutic window and support further clinical development and potential orphan/first‑in‑class positioning.

Analysis

Akiram Therapeutics has completed cohort 2a of its Phase I dose-escalation trial of 177Lu-AKIR001 and reports that the higher activity dose tested produced no dose-limiting toxicities and showed encouraging tumor uptake; the trial is sponsored and conducted at Karolinska University Hospital (ClinicalTrials.gov NCT06639191). The Safety Review Committee approved initiation of cohort 2b, which will increase the protein dose while keeping the same lutetium-177 activity, explicitly to identify the most favorable protein dose for remaining cohorts and further development.

Consistent safety across the run-in and cohort 2a and the reported tumor uptake reduce near-term development risk by validating tolerability and target engagement for this CD44v6-directed radioimmunotherapy. Protein-dose optimization is presented as a central next step to define a therapeutic window, which is critical for selecting a recommended phase II dose and for regulatory positioning including potential orphan or first-in-class status.

The program retains typical Phase I uncertainties: current readouts are safety and pharmacokinetics rather than definitive efficacy, and broader efficacy and larger-cohort tolerability remain unproven. Positive preclinical dosimetry and institutional backing (Karolinska) and support from Swedish research funders are constructive, so near-term investor-relevant catalysts are cohort 2b data, subsequent dose-escalation readouts, and any regulatory or partnership signals.

Key Decisions for Investors

• Monitor cohort 2b protein-dose escalation readouts and any quantitative safety/tumor uptake metrics closely before increasing exposure; treat near-term moves as catalyst-driven trading opportunities
• Maintain only a small, speculative position until the trial demonstrates consistent tolerability at the optimized protein dose and early signs of antitumor activity, avoid allocating significant capital on Phase I safety data alone
• Watch for regulatory milestones (orphan designation prospects) and partnership or financing announcements that would materially de-risk the program and justify reweighting the position
• Set alerts for ClinicalTrials.gov updates, Safety Review Committee statements, and investigator readouts from Karolinska as primary decision triggers for buying, holding, or exiting